IGM Biosciences Newsroom

Maintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical Data

TipRanksMay 24 06:30 ET

IGM Biosciences Analyst Ratings

BenzingaMay 24 06:22 ET

IGM Biosciences Analyst Ratings

BenzingaMay 9 08:51 ET

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)

TipRanksMay 9 08:25 ET

Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)

TipRanksApr 18 14:30 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)

TipRanksApr 18 06:36 ET

IGM Biosciences Analyst Ratings

BenzingaApr 18 06:34 ET

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)

TipRanksMar 19 08:55 ET

IGM Biosciences Analyst Ratings

BenzingaMar 12 06:47 ET

IGM Biosciences: A Balanced Hold Rating Amid Financial Stability and Drug Development Risks

TipRanksMar 12 06:30 ET

IGM Biosciences Analyst Ratings

BenzingaMar 8 10:12 ET

Analysts Offer Insights on Healthcare Companies: Joint (JYNT), IGM Biosciences (IGMS) and Optinose (OPTN)

TipRanksMar 8 09:05 ET

Analysts' Top Healthcare Picks: Inventiva (IVA), IGM Biosciences (IGMS)

TipRanksMar 8 08:35 ET

RBC Capital Sticks to Their Buy Rating for IGM Biosciences (IGMS)

TipRanksMar 8 07:31 ET

IGM Biosciences Analyst Ratings

BenzingaFeb 9 10:31 ET

IGM Biosciences Shares Upgraded to Outperform on $1B+ Long-term Opportunity

InvestingFeb 9 08:58 ET

RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept

MT NewswiresFeb 9 07:33 ET

B of A Securities Downgrades IGM Biosciences to Neutral, Announces $8 Price Target

BenzingaDec 15, 2023 08:39 ET

IGM Biosciences Analyst Ratings

BenzingaDec 15, 2023 08:38 ET

HC Wainwright & Co. Downgrades IGM Biosciences to Neutral, Lowers Price Target to $7

BenzingaDec 7, 2023 11:10 ET